New POC allergy test has been cleared by FDA
The US medical agency FDA has granted Phadia the clearance to sell and market its new POC allergy test ImmunoCAP® Rapid product in US.
“This is a historical event in the diagnostic industry since it is the first semi-quantitative POC allergy test that has been FDA cleared. It is a major milestone for Phadia in building the ImmunoCAP franchise even stronger and will provide more patients with allergy-like symptoms the possibility to get a correct diagnosis” says Håkan Englund, Executive Vice President Phadia AB.
ImmunoCAP Rapid will be introduced on the US market later in the year. The European version of ImmunoCAP Rapid has been marketed and sold in selected European countries for over 2 years.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.